Tryptase levels after suxamethonium administration and defibrillation

Area of Science:

• Anesthesiology
• Emergency Medicine
• Clinical Chemistry

Background:

• A threefold increase in tryptase levels is a key indicator for diagnosing anaphylaxis.
• Elevated tryptase can also result from trauma, ischemia, and non-IgE mediated drug reactions.
• The study investigated if suxamethonium or defibrillation could cause a significant tryptase rise without anaphylaxis.

Purpose of the Study:

• To determine if suxamethonium or defibrillation can elevate serum tryptase levels.
• To assess if these procedures cause a >3-fold increase in tryptase in the absence of anaphylaxis symptoms.
• To clarify the diagnostic utility of tryptase in differentiating anaphylaxis from other medical events.

Main Methods:

• Serum tryptase (S-tryptase) was measured in 50 patients undergoing anesthesia.
• Patients received either suxamethonium for electroconvulsive therapy (ECT) or propofol for atrial fibrillation cardioversion.
• Blood samples were collected pre-procedure and 1 hour post-procedure.

Main Results:

• No significant difference in tryptase levels was observed before and after the procedures.
• Suxamethonium administration during ECT did not lead to a significant tryptase increase.
• Defibrillation with propofol anesthesia did not result in elevated tryptase levels.

Conclusions:

• Elective defibrillation or ECT with suxamethonium does not elevate tryptase levels in the absence of anaphylaxis symptoms.
• These findings support the reliability of tryptase measurements in diagnosing anaphylaxis, even after these interventions.
• Tryptase levels remain a specific marker for anaphylaxis, unaffected by suxamethonium or defibrillation in non-anaphylactic states.